AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 152 filers reported holding AKERO THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 1.85 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,074,185 | +9.2% | 41,008 | +0.8% | 0.02% | +6.2% |
Q2 2023 | $1,898,649 | +61.0% | 40,665 | +32.0% | 0.02% | +60.0% |
Q1 2023 | $1,178,944 | -32.2% | 30,814 | -2.9% | 0.01% | -37.5% |
Q4 2022 | $1,738,530 | +148.4% | 31,725 | +54.4% | 0.02% | +128.6% |
Q3 2022 | $700,000 | +257.1% | 20,548 | -1.1% | 0.01% | +250.0% |
Q2 2022 | $196,000 | -61.6% | 20,777 | -42.3% | 0.00% | -66.7% |
Q1 2022 | $511,000 | -40.2% | 35,984 | -10.9% | 0.01% | -40.0% |
Q4 2021 | $854,000 | -10.6% | 40,373 | -5.5% | 0.01% | +11.1% |
Q3 2021 | $955,000 | -16.1% | 42,729 | -6.9% | 0.01% | -10.0% |
Q2 2021 | $1,138,000 | -37.5% | 45,872 | -27.0% | 0.01% | -44.4% |
Q1 2021 | $1,822,000 | +12.6% | 62,814 | +0.1% | 0.02% | 0.0% |
Q4 2020 | $1,618,000 | +18.8% | 62,722 | +41.7% | 0.02% | -10.0% |
Q3 2020 | $1,362,000 | +39.7% | 44,249 | +13.1% | 0.02% | +53.8% |
Q2 2020 | $975,000 | -11.4% | 39,113 | -24.7% | 0.01% | -23.5% |
Q1 2020 | $1,101,000 | -14.5% | 51,918 | -10.4% | 0.02% | +70.0% |
Q4 2019 | $1,287,000 | – | 57,975 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Skorpios Trust | 3,271,829 | $125,180,178 | 50.58% |
COMMODORE CAPITAL LP | 790,000 | $30,225,400 | 4.60% |
Redmile Group, LLC | 2,044,389 | $78,218,323 | 3.39% |
SILVERARC CAPITAL MANAGEMENT, LLC | 202,561 | $7,749,984 | 3.20% |
Ghost Tree Capital, LLC | 275,000 | $10,522,000 | 3.11% |
Avidity Partners Management LP | 2,447,000 | $93,622,220 | 3.11% |
Atlas Venture Life Science Advisors, LLC | 594,251 | $22,736,043 | 3.08% |
Logos Global Management LP | 400,000 | $15,304,000 | 2.19% |
Yiheng Capital Management, L.P. | 1,125,791 | $43,072,764 | 1.70% |
Boxer Capital, LLC | 831,495 | $31,813 | 1.56% |